Publications by authors named "Ciro Florio"

Claim this Profile
O
One year experience with erenumab: real-life data in 30 consecutive patients.
Angelo Ranieri, Gennaro Alfieri, Massimo Napolitano, Giovanna Servillo, Paolo Candelaresi, Ciro Florio

Neurol Sci· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project.
Giorgia Teresa Maniscalco, Vincenzo Brescia Morra, Ciro Florio, Giacomo Lus, Gioacchino Tedeschi

Pharmaceuticals (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Maria Pia Amato, Mattia Fonderico, Emilio Portaccio, Luisa Pastò, Lorenzo Razzolini, Ciro Florio

Brain· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GABA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis.
Giorgia Teresa Maniscalco, Sara Mariotto, Romana Höftberger, Ruggero Capra, Giovanna Servillo, Ciro Florio

Neurology· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis.
Giorgia T Maniscalco, Mario Annunziata, Angelo Ranieri, Gennaro Alfieri, Rosaria Renna, Ciro Florio

Mult Scler Relat Disord· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration.
Claudia La Rocca, Fortunata Carbone, Veronica De Rosa, Alessandra Colamatteo, Mario Galgani, Ciro Florio

Metabolism· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Roberta Lanzillo, Mario Quarantelli, Carlo Pozzilli, Maria Trojano, Maria Pia Amato, Ciro Florio

Mult Scler· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Diego Bertoli, Federico Serana, Alessandra Sottini, Cinzia Cordioli, Davide Maimone, Ciro Florio

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Pietro B Carrieri, Fortunata Carbone, Francesco Perna, Dario Bruzzese, Claudia La Rocca, Ciro Florio

Metabolism· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Alessandra Lugaresi, Ciro Florio, Vincenzo Brescia-Morra, Salvatore Cottone, Paolo Bellantonio

BMC Neurol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: a case report.
Ciro Florio, Giorgia Teresa Maniscalco

Neurol Sci· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIRs and their HLA ligands in remitting-relapsing multiple sclerosis.
Caterina Fusco, Franca Rosa Guerini, Giustina Nocera, Gianluca Ventrella, Domenico Caputo, Ciro Florio

J Neuroimmunol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
Pietro B Carrieri, Paolo Ladogana, Gaetano Di Spigna, Maria Fulvia de Leva, Maria Petracca, Ciro Florio

Immunopharmacol Immunotoxicol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
Roberta Lanzillo, Anna Prinster, Valentina Scarano, Raffaele Liuzzi, Giovanni Coppola, Ciro Florio

J Neurol Sci· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis